Sexually Transmitted Infections and Prostate Cancer among Men in the US Military

被引:30
作者
Dennis, Leslie K. [1 ]
Coughlin, Julie A. [1 ]
McKinnon, Brittany C. [1 ]
Wells, Timothy S. [2 ]
Gaydos, Charlotte A. [3 ]
Hamsikova, Eva [4 ]
Gray, Gregory C. [1 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA
[2] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA
[3] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA
[4] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic
关键词
SIMPLEX-VIRUS TYPE-2; HUMAN-PAPILLOMAVIRUS INFECTION; RISK-FACTORS; UNITED-STATES; CHLAMYDIA-TRACHOMATIS; SEROLOGIC EVIDENCE; DISEASES; METAANALYSIS; ASSOCIATION; HUMAN-PAPILLOMAVIRUS-18;
D O I
10.1158/1055-9965.EPI-08-1167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Studies of self-reported sexually transmitted infections (STI) suggesting an association with prostate cancer may reflect underreporting of such infections among nondiseased subjects. To reduce such bias, we studied archived sera in a cohort of U.S. military personnel known to have high rates of both STIs and prostate cancer. Using a nested case-control design, serum samples from 534 men who served on active duty between September 1, 1993 and September 1, 2003 were examined. Controls were individually matched to cases based on date of serum collection, date of birth, branch of service, military rank, marital status, and race. Each of the 267 case-control pairs had two serum samples: a recent serum sample, taken similar to 1 year before the case's prostate cancer diagnosis, and an earlier serum sample, taken similar to 8 years before diagnosis. Each serum specimen was studied for antibodies against human papillomavirus, herpes simplex virus-2 (HSV-2), and Chlamydia trachomatis. Logistic regression accounted for matching and potential confounding factors. Study data indicated no association between prostate cancer and serologic evidence of infections just before the reference date. However, a statistically significant association between prostate cancer and serologic evidence of HSV-2 infection was detected in the earlier sample (odds ratio, 1.60; 95% confidence interval, 1.05-2.44). The strength of this association increased when analyses were restricted to sera collected at least 60 months before diagnosis (odds ratio, 2.04; 95% confidence interval, 1.26-3.29; 204 pairs). If this association is causal, then our findings would suggest a long latency period for prostate cancer development after HSV-2 infection. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2665-71)
引用
收藏
页码:2665 / 2671
页数:7
相关论文
共 41 条
[1]  
Adami HO, 2003, CANCER EPIDEM BIOMAR, V12, P872
[2]   Army and air force leadership in the prostate cancer prevention trial [J].
Allerton, J ;
Seay, T ;
Optenberg, S ;
Coltman, CA ;
Higgins, B ;
Thompson, I ;
Lovato, L .
UROLOGY, 1998, 51 (4A) :64-66
[3]  
[Anonymous], 2009, SEER Cancer Statistics Review, 1975-2006
[4]  
[Anonymous], STAT METHODS CANC RE, DOI DOI 10.1097/00002030-199912240-00009
[5]   Chlamydial antibodies and risk of prostate cancer [J].
Anttila, T ;
Tenkanen, L ;
Lumme, S ;
Leinonen, M ;
Gislefoss, RE ;
Hallmans, G ;
Thoresen, S ;
Hakulinen, T ;
Luostarinen, T ;
Stattin, P ;
Saikku, P ;
Dillner, J ;
Lehtinen, M ;
Anttila, T ;
Tenkanen, L ;
Lumme, S ;
Leinonen, M ;
Gislefoss, RE ;
Hallmans, G ;
Thoresen, S ;
Hakulinen, T ;
Luostarinen, T ;
Stattin, P ;
Saikku, P ;
Dillner, J ;
Lehtinen, M ;
Hakama, M .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) :385-389
[6]  
BOLDOGH I, 1983, JNCI-J NATL CANCER I, V70, P819
[7]   MEDICAL, LIFE-STYLE, AND OCCUPATIONAL RISK-FACTORS FOR PROSTATE-CANCER [J].
CHECKOWAY, H ;
DIFERDINANDO, G ;
HULKA, BS ;
MICKEY, DD .
PROSTATE, 1987, 10 (01) :79-88
[8]   Meta-analysis of measures of sexual activity and prostate cancer [J].
Dennis, LK ;
Dawson, DV .
EPIDEMIOLOGY, 2002, 13 (01) :72-79
[9]   Epidemiologic association between prostatitis and prostate cancer [J].
Dennis, LK ;
Lynch, CF ;
Torner, JC .
UROLOGY, 2002, 60 (01) :78-83
[10]  
Dillner J, 1998, INT J CANCER, V75, P564, DOI 10.1002/(SICI)1097-0215(19980209)75:4<564::AID-IJC12>3.0.CO